Onesource Specialty Pharma Share News - Latest Updates, Live News & More

Latest news about Onesource Specialty Pharma

Onesource Speciality Pharma Promoter Group Increases Stake to 30.10% Through Open Market Purchase 1 day ago Yesterday

Tenshi Pharmaceuticals Private Limited, part of Onesource Speciality Pharma's promoter group, acquired 2,00,000 equity shares (0.17%) through open market purchase on January 28, 2026. This acquisition increased the combined promoter group holding from 29.93% to 30.10% of the company's total voting capital. The disclosure was made under SEBI Regulation 29(2) for substantial acquisition of shares, with the company's total equity capital remaining at 11,45,62,136 shares of Rs. 1 each.

OneSource Specialty Pharma Reports Q3 FY26 Financial Results with Revenue of ₹2,903.40 Million 6 days ago

OneSource Specialty Pharma Allots 36,065 Equity Shares Under ESOP 2021 to Eligible Employees 8 days ago

OneSource Specialty Pharma Schedules Q3FY26 Earnings Call for January 24, 2026 10 days ago

OneSource Specialty Pharma Board Meeting Scheduled for January 23, 2026 to Review Q3FY26 Financial Results 10 days ago

More news about Onesource Specialty Pharma

14Jan 26

OnSource Specialty Pharma Merges Singapore Subsidiary Stelis Pte. Limited With OnSource Specialty Pte. Limited

OnSource Specialty Pharma has completed the merger of its Singapore subsidiary Stelis Pte. Limited with OnSource Specialty Pte. Limited. This corporate restructuring consolidates two Singapore-based entities, representing a strategic move to streamline the company's subsidiary structure and enhance operational efficiency in the Singapore market.

09Jan 26

Onesource Specialty Pharma Creates Share Pledge for ₹1,000 Crore Debenture Issuance

Onesource Specialty Pharma Ltd has announced that Catalyst Trusteeship Limited has created a pledge over 64,00,000 equity shares, representing 5.59% of the company's total share capital. The pledge arrangement is established in connection with a ₹1,000 crore debenture issuance, providing security for this substantial debt financing initiative. This development highlights the company's capital market activities and structured approach to debt financing.

09Jan 26

OneSource Specialty Pharma: Tenshi Pharmaceuticals Pledges 64 Lakh Shares for ₹1000 Crore Debenture Security

OneSource Specialty Pharma Limited disclosed that Tenshi Pharmaceuticals Private Limited pledged 64,00,000 equity shares (5.59% stake) to Catalyst Trusteeship Limited as security for ₹1000 crore debentures. The encumbrance was created on January 05, 2026, under agreements dated November 27, 2025, to secure financial indebtedness by group company Karuna Ventures Private Limited. This represents the second tranche of pledging, following an earlier pledge of 20,00,000 shares in December 2025.

19Dec 25

Onesource Specialty Pharma: Promoter Pledges 20 Lakh Shares for Business Requirements

Tenshi Pharmaceuticals Private Limited, a promoter entity of Onesource Specialty Pharma Limited, has pledged 20,00,000 equity shares on December 16, 2025. The pledge was made to address business and operational needs of the promoter entity. The company disclosed this information in a regulatory filing on December 18, 2025, in compliance with SEBI regulations.

18Nov 25

ONESource Specialty Pharma Withdraws from Jefferies Global Healthcare Conference

ONESource Specialty Pharma has announced its withdrawal from the upcoming Jefferies Global Healthcare Conference scheduled for November 18-20, 2025, in London. The company cited 'urgent matters' as the reason for their absence. This decision may impact the company's planned interactions with investors and industry analysts. The official notice was signed by Trisha A, the Company Secretary and Compliance Officer.

12Nov 25

OneSource Specialty Pharma Reports 12% Revenue Growth in Q2FY26, Raises FY28 Outlook

OneSource Specialty Pharma, a CDMO, reported robust Q2FY26 results with revenue up 12% to ₹3,758 million and EBITDA margin increasing by 506 basis points to 28%. The company signed 9 new MSAs, expanded its drug-device-combinations capabilities, and is accelerating capacity expansion. OneSource entered into a Composite Scheme of Arrangement and Amalgamation, proposing acquisitions to enhance its global footprint. The biologics funnel saw a 4x increase compared to FY25. Based on performance and strategic initiatives, the company raised its FY28 revenue outlook to $500 million with an expected 40% EBITDA margin.

11Nov 25

OneSource Specialty Pharma Reports Q2 FY2025-26 Results: Swings to Profit, Revenue Up 15.7%

OneSource Specialty Pharma reported a consolidated net profit of ₹104.85 million for Q2 FY2025-26, compared to a ₹1.86 million loss in Q1, as revenue rose 15.7% QoQ to ₹3,787.63 million. For H1 FY2025-26, revenue reached ₹7,060.33 million with a profit of ₹102.99 million, marking a turnaround from last year’s loss. Management highlighted stronger CDMO order flow, improved utilization, and a focus on margin expansion.

26Sept 25

OneSource Specialty Pharma Unveils Ambitious Multi-Company Merger Plan

OneSource Specialty Pharma has approved a restructuring plan involving the merger of four companies to strengthen its CDMO sector position. The plan includes merging Steriscience Specialties, Brooks Steriscience, Steriscience Pte, and Strides Pharma Services into OneSource. Share exchange ratios have been set for the mergers. Post-merger, promoter shareholding is expected to increase to 36.17% from 29.77%. The consolidation aims to enhance CDMO capabilities, expand European operations, improve efficiency, and enable global expansion. Financial restructuring to address past losses is also part of the plan. The scheme requires approvals from various regulatory authorities.

12Aug 25

OneSource Specialty Pharma Reports Strong Q1 Results, Evaluates Strategic Acquisitions

OneSource Specialty Pharma Limited reported robust Q1 financial performance with 12% revenue growth to INR 3,273 million and 37% EBITDA growth to INR 885 million. The company is accelerating capacity expansion for drug-device combinations and exploring potential acquisitions in Poland and India. These acquisitions could add $100 million in revenue potential by FY27. OneSource also announced a strategic partnership with Xbrane Biopharma to strengthen its drug substance business.

04Aug 25

OneSource Specialty Pharma Explores Acquisition of Sterile Injectable Businesses, Reports Q1 Results

OneSource Specialty Pharma is evaluating the acquisition of sterile injectable businesses from Steriscience Pte. Limited and Brooks Steriscience Limited, including facilities in Poland and India. The company also reported Q1 financial results with 12% revenue growth to ₹3,273 million, 37% EBITDA increase to ₹885 million, and a profit of ₹371 million compared to a loss in the previous year. The company secured 6 new contracts and received 25 RFPs during the quarter.

04Aug 25

OneSource Specialty Pharma Allots 23,000 ESOP Shares, Paid-Up Capital Rises

OneSource Specialty Pharma completed allotment of 23,000 equity shares under Employee Stock Option Plan 2021, raising paid-up share capital to ₹11.46 crores. The company showed improved financial performance in Q1 FY26 with significantly reduced consolidated losses and revenue growth, while exploring strategic acquisitions to expand its CDMO capabilities.

10Jun 25

ONESOURCE Specialty Pharma Secures VAI Classification from USFDA for Bangalore Facility

ONESOURCE Specialty Pharma has received a 'Voluntary Action Indicated' (VAI) classification from the U.S. Food and Drug Administration for its manufacturing facility in Bangalore, India. This classification indicates that while minor issues were observed, they do not require regulatory action. The VAI status validates the company's compliance with regulatory standards and allows continued operations without significant hurdles. It positions ONESOURCE favorably in the pharmaceutical industry, especially for the U.S. market, while also indicating areas for minor improvements.

10Apr 25

OneSource Specialty Pharma's Unit 2 Secures ANVISA GMP Certification, Expanding Market Reach to Brazil

OneSource Specialty Pharma's Unit 2 in Bengaluru has obtained GMP certification from ANVISA, Brazil's Health Regulatory Agency, following a November 2024 inspection. This approval allows the company to supply Drug-Device Combinations and GLP-1s to the Brazilian market, subject to product approvals. The certification is particularly significant as Brazil is expected to be a major market for generic Semaglutide in 2026. OneSource, formerly Stelis Biopharma, is an Indian specialty pharma CDMO with five globally approved facilities.

07Mar 25

SEBI Guidance Halts OneSource Specialty Pharma's QIP Plans Post-Listing

OneSource Specialty Pharma, a newly listed pharmaceutical company, faces a setback in its capital raising plans due to SEBI guidance. The company is prohibited from conducting a Qualified Institutional Placement (QIP) immediately after listing, owing to its involvement in a merger with an unlisted entity prior to going public. SEBI mandates a one-year waiting period post-listing before OneSource can initiate a QIP. This delay may impact the company's short-term growth strategies and force it to seek alternative funding sources.